Skip to main content
. Author manuscript; available in PMC: 2014 Nov 24.
Published in final edited form as: J Thorac Oncol. 2010 Nov;5(11):1821–1825. doi: 10.1097/JTO.0b013e3181f1d23c

TABLE 2.

Characteristics of Treatment with the Study Drugs

Characteristics Patients, n = 47 (%)
Number of cycles
  Median 8
  Range 1–42
Treatment interruption
  Disease progression 32 (68.1)
  Adverse events or toxicity 7 (14.9
Dose reduction 34 (72.3)
GSCF 7 (14.9)

GSCF, granulocyte colony-stimulating factor.